Merrill keeps Adams Respiratory at neutral

Adams Respiratory Therapeutics Inc. was maintained at its neutral rating by Merrill Lynch analyst Gregg Gilbert, based on IRI data reporting Mucinex sales of $61 million for the 11 weeks ended March 12. Merrill believes if sales remain flat, third-quarter sales could be roughly $72 million, compared with the analyst's estimate of $73 million. With the onset of the spring allergy season, Mucinex D usage for allergy symptoms could potentially offset some of the falloff in Mucinex SE and DM sales as the cough/cold/flu season winds down. Shares of the Chester, N.J., specialty pharmaceutical company were up 19 cents, or 0.49%, at $38.84 on volume of 194,150 shares versus the three-month running average of 354,202 shares. (Nasdaq: ARXT)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.